Aardvark Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Aardvark Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, is 1.3 times its market value (net cash). Higher than 91% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 0 of the last 3 years; profit grew in 1 of 3. Less steady than 86% of Healthcare companies in United States.
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-122.8×Operating cash was negative last year, while some debt falls due within a year.
Lower than 86% of Healthcare companies in United States.
Cash Cushion Ratio
1.3× cashCash, after subtracting all debt, is 1.3 times its market value (net cash).
Higher than 91% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Aardvark Therapeutics, Inc. made a loss over the last year. Aardvark Therapeutics, Inc. owes $0.08 for every $1 it owns. Aardvark Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossAardvark Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.16The share price is 1.16 times Aardvark Therapeutics, Inc.'s book value per share, lower than 76% of Healthcare companies in United States.
Market cap
$86 MThe total market value of all of Aardvark Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 68% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$75 MWhat Aardvark Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$3.42Net worth divided by the number of shares. The share price of $3.95 is 1.2 times this, which is the P/B above.
Return on equity (ROE)
-66.0%Aardvark Therapeutics, Inc. lost 66.0% of its shareholders' money over the last year, lower than 60% of Healthcare companies in United States.
Owes vs Owns
0.08×Aardvark Therapeutics, Inc. owes $0.08 for every $1 it owns (low), lower than 90% of Healthcare companies in United States.
Dividend yield
NoneAardvark Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossAardvark Therapeutics, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashAardvark Therapeutics, Inc. held $110 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Aardvark Therapeutics, Inc.: $86 M ÷ $75 M (30 Jun 2026) = 1.2.
What is Aardvark Therapeutics, Inc.'s return on equity?
Aardvark Therapeutics, Inc. lost 66.0% of its shareholders' money over the last year, lower than 60% of Healthcare companies in United States.
How much does Aardvark Therapeutics, Inc. owe compared with what it owns?
Aardvark Therapeutics, Inc. owes $0.08 for every $1 it owns (low), lower than 90% of Healthcare companies in United States.
Does Aardvark Therapeutics, Inc. pay a dividend?
No. Aardvark Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.